Patents Examined by Niloofar Rahmani
  • 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
    Patent number: 11491140
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: November 8, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction
    Patent number: 11479545
    Abstract: The present disclosure relates to the field of medicinal chemistry, in particular to a phenyl triazole MLL1-WDR5 protein-protein interaction inhibitor (I) and a preparation method thereof, and pharmacodynamics experiments prove that the compound of the present disclosure has relatively strong MLL1-WDR5 protein-protein interaction inhibition activity.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: October 25, 2022
    Assignee: China Pharmaceutical University
    Inventors: Qidong You, Xiaoke Guo, Dongdong Li, Weilin Chen, Zhihui Wang
  • Compounds and compositions for treating conditions associated with APJ receptor activity
    Patent number: 11471455
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor, gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: October 18, 2022
    Assignee: ANNAPURNA BIO, INC.
    Inventors: Haifeng Tang, Michael Hanson, Sarah Boyce, Zhe Nie
  • Salts and crystal forms of omecamtiv mecarbil
    Patent number: 11465969
    Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 11, 2022
    Assignees: CYTOKINETICS, INC., AMGEN INC.
    Inventors: Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Ailsa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
  • Crystalline polymorphs of Pracinostat and Pracinostat salts
    Patent number: 11465974
    Abstract: The present disclosure encompasses crystalline polymorphs of Pracinostat and of Pracinostat salts, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 11, 2022
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Jenny Goldshtein, Maytal Piran, Doron Rudik, Rotem Sella-Erez, Sharona Alfasie Shachan-Tov, Ofir Shaul
  • Modulators of the NMDA receptor
    Patent number: 11466027
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof
    Patent number: 11459327
    Abstract: Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and the use thereof are described. Compounds of the present invention have a structure represented by formula (I). Further disclosed are preparation methods for said compounds, and the use of said compounds as KRASG12C inhibitors. The compounds have an excellent ability to selectively inhibit KRASG12C, improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: October 4, 2022
    Assignees: Suzhou Zelgen Biopharmaceuticals Co., Ltd., Shanghai Zelgen Pharma.Tech Co., Ltd.
    Inventors: Binhua Lv, Dawei Cui, Lianjun Liu, Tao Han, Runqing Wang, Peizhong Ni, Zelin Sheng
  • Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
    Patent number: 11453667
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: September 27, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Zhaobing Xu, Hailong Yang, Shiqi Han, Guoping Hu, Lihong Hu, Charles Z. Ding, Jian Li, Shuhui Chen
  • Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
    Patent number: 11447505
    Abstract: The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: September 20, 2022
    Assignee: Cancer Research Technology Limited
    Inventors: Angelo Pugliese, Stuart Francis, Duncan McArthur, Mairi Sime, Justin Bower, Simone Belshaw
  • Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use
    Patent number: 11427582
    Abstract: Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis; depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: August 30, 2022
    Assignee: UWM Research Foundation, Inc.
    Inventors: James Cook, Daniel Knutson
  • Modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 11426407
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 30, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Compounds useful for treating cancer
    Patent number: 11427566
    Abstract: A compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: August 30, 2022
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
  • 6-azaindole compounds
    Patent number: 11427580
    Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: August 30, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
  • Imidazo-pyridine compounds as PAD inhibitors
    Patent number: 11426412
    Abstract: Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: August 30, 2022
    Assignee: JUBILANT EPIPAD LLC
    Inventors: Gurulingappa Hallur, Athisayamani Jeyaraj Duraiswamy, Buchi Reddy Purra, N.V.S.K. Rao, Sridharan Rajagopal, Rajendra Kristam
  • Synergists for quinacridone magenta pigments
    Patent number: 11427557
    Abstract: Disclosed herein are compositions (e.g.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: August 30, 2022
    Assignee: Cabot Corporation
    Inventors: Alexander I. Shakhnovich, Heather E. Clarke
  • Solid state forms of Pemafibrate
    Patent number: 11420945
    Abstract: The present disclosure relates to solid state forms of Pemafibrate processes for preparation thereof and pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 23, 2022
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Pavel Kolesa, Andrea Colombo, Ettore Marzorati
  • Substituted pyrrolopyridines as JAK inhibitors
    Patent number: 11420966
    Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: August 23, 2022
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Paramita Mukherjee, Paul Changelian, Canxin Xu
  • Compounds and uses thereof
    Patent number: 11414416
    Abstract: The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: August 16, 2022
    Assignee: Foghorn Therapeutics Inc.
    Inventors: Sabine K. Ruppel, Zhaoxia Yang, Jason T. Lowe, Johannes H. Voigt, Matthew Netherton
  • Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
    Patent number: 11407771
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 9, 2022
    Assignee: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu
  • Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase
    Patent number: 11407767
    Abstract: This invention related to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by the CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular, the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 9, 2022
    Inventors: David Brook, Chris Hayes, Nicholas Bennett, Matthew Palframan, Sue Cramp, Richard Bull, Michael Bodnarchuk